# A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects

> **NCT01923207** · PHASE1 · COMPLETED · sponsor: **Shire** · enrollment: 32 (actual)

## Conditions studied

- Hereditary Angioedema (HAE)

## Interventions

- **DRUG:** DX-2930
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01923207
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-12
- **Primary completion:** 2014-01-07
- **Final completion:** 2014-01-07
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2021-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01923207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01923207, "A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01923207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*